News in Brief
Pharmacology - Oct 23
Novartis announces European Medicines Agency (EMA) has granted orphan drug designation for iptacopan (LNP023) in IgA nephropathy (IgAN)
Novartis announces European Medicines Agency (EMA) has granted orphan drug designation for iptacopan (LNP023) in IgA nephropathy (IgAN)
wire - news in brief
Category
Results 101 - 150 of 427.
A bioethicist and a neuroinformatics scientist discuss how machines are becoming more intelligent and why the advances in technology are leading to new ethical challenges.
The Inga hope a university will keep their indigenous heritage alive, safeguard the natural habitat of the Colombian rainforest and give the younger generation a future.
European Medicines Agency (EMA) approves safety label update for Novartis Beovu
Novartis worked with the EMA to update the Beovu (brolucizumab) label to guide physicians in their treatment of wet AMD The update includes the additional characterization of retinal vasculitis a
Novartis worked with the EMA to update the Beovu (brolucizumab) label to guide physicians in their treatment of wet AMD The update includes the additional characterization of retinal vasculitis a
Putting the users centre stage
Even if we succeed in combatting the COVID crisis, the challenges for the health system will not simply disappear. Digital technologies can be developed to help meet ongoing challenges; Nicole Wenderoth explains what should be borne in mind here. Across the globe, the COVID-19 pandemic has pushed healthcare systems to their limits, at least for the moment.
Even if we succeed in combatting the COVID crisis, the challenges for the health system will not simply disappear. Digital technologies can be developed to help meet ongoing challenges; Nicole Wenderoth explains what should be borne in mind here. Across the globe, the COVID-19 pandemic has pushed healthcare systems to their limits, at least for the moment.
Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta (ofatumumab) in newly diagnosed treatment-naļve adults with relapsing multiple sclerosis
New post hoc data from Phase III ASCLEPIOS trials showed newly diagnosed, treatment-naļve patients experienced reductions in annualized relapse rates, MRI lesion activity and reductions in time to di
New post hoc data from Phase III ASCLEPIOS trials showed newly diagnosed, treatment-naļve patients experienced reductions in annualized relapse rates, MRI lesion activity and reductions in time to di
Coronavirus: No quarantine for persons entering from border regions
At its meeting on 11 September, the Federal Council decided on the quarantine rules for persons entering Switzerland from neighbouring countries: only those regions of neighbouring countries where th
At its meeting on 11 September, the Federal Council decided on the quarantine rules for persons entering Switzerland from neighbouring countries: only those regions of neighbouring countries where th
On September 14, an expedition within the framework of the international project Ice Memory is setting out to carry out ice core drilling on the glacier of the mountain massif Grand Combin in the Swiss canton of Valais.
Process Engineer Adriano Joss from Eawag water research institute has been working for many years on wastewater treatment plants and the removal of micropollutants from water.
The FMI is a partner of the pan-European LifeTime initiative. In two publications, researchers involved with the initiative - including FMI group leader Susan Gasser - present a detailed roadmap of how to leverage the latest scientific breakthroughs and technologies over the next decade, to track, understand and treat human cells throughout an individual's lifetime.
Efforts are being made worldwide to combat the new coronavirus SARS-CoV-2. Vaccines and protective masks are of prime importance. Empa researcher Peter Wick, Head of the Particles-Biology Interactions Laboratory in St. Gallen, talks to Empa Quarterly about recent antibody studies, which are crucial for the development of a COVID-19 vaccine, and the next generation of textile protective materials that inactivate or even kill corona viruses.
Molecular glue degraders are a new class of drugs that work by facilitating an interaction between a disease-causing target protein and a ubiquitin ligase complex, tagging the target protein for degradation.
Novartis post hoc analysis shows high-dose Enerzair Breezhaler reduces asthma exacerbations versus medium-dose, complementing key pivotal IRIDIUM study findings
High-dose, once-daily Enerzair Breezhaler [IND/GLY/MF] reduced asthma exacerbation rates by 21% (moderate or severe) and 31% (severe) versus medium-dose, over 52 weeks 1 Once-daily Enerzair Breezhale
High-dose, once-daily Enerzair Breezhaler [IND/GLY/MF] reduced asthma exacerbation rates by 21% (moderate or severe) and 31% (severe) versus medium-dose, over 52 weeks 1 Once-daily Enerzair Breezhale
Two talented young researchers at Empa will be given the opportunity to develop their own research area over a five-year period with the help of an ERC Starting Grant from the European Research Counc
ETH has once again been highly successful in the awarding of this year's ERC Starting Grants for young researchers, with the European Research Council (ERC) approving a total of CHF 21.4 million in funding for 12 ETH project submissions.
Novartis announces NEJM publication of pivotal study of Tabrecta(TM) in patients with METex14 metastatic non-small cell lung cancer
Tabrecta(TM) (capmatinib, formerly INC280) is the first and only therapy approved by the FDA to specifically target metastatic non-small cell lung cancer (NSCLC) with a mutation that leads to MET exo
Tabrecta(TM) (capmatinib, formerly INC280) is the first and only therapy approved by the FDA to specifically target metastatic non-small cell lung cancer (NSCLC) with a mutation that leads to MET exo
How the Swiss fared under partial lockdown
A joint study by EPFL, the Idiap Research Institute and the University of Lausanne's Institute of Psychology has provided us with a unique snapshot of how Swiss residents experienced the partial lockdown measures resulting from the coronavirus pandemic. The findings include gender disparities, doubts about the future and hopes for change.
A joint study by EPFL, the Idiap Research Institute and the University of Lausanne's Institute of Psychology has provided us with a unique snapshot of how Swiss residents experienced the partial lockdown measures resulting from the coronavirus pandemic. The findings include gender disparities, doubts about the future and hopes for change.
Organoid? was launched today. It aims at validating organoids as faithful models of human biology, combining single-cell profiling and organoid technology.
As impressive as they may be, the latest AI systems are still no match for humans. Benjamin Grewe pushes for tomorrow's intelligent machines to learn the way young children do.
Novartis new analysis shows high consistency in lowering LDL-C in individual response with investigational inclisiran
Pooled data from Phase III ORION-10 and -11 showed highly consistent efficacy, tolerability and safety profile over 17 months on twice-yearly subcutaneous dosing in 2,300 patients (of which 1,164 wer
Pooled data from Phase III ORION-10 and -11 showed highly consistent efficacy, tolerability and safety profile over 17 months on twice-yearly subcutaneous dosing in 2,300 patients (of which 1,164 wer
The fact that there are many different types of infinities is one of the big puzzles in mathematics.
The review paper "Rethinking wastewater risks and monitoring in light of the COVID-19 pandemic" was co-authored by 34 contributors from around the world. What was Eawag's contribution? Eberhard Morgenroth: For May 2020 I had been invited to participate in the "International Water Summit" at the Ben-Gurion University in Israel.
News in Brief
Pharmacology - Oct 23
Novartis announces European Medicines Agency (EMA) has granted orphan drug designation for iptacopan (LNP023) in IgA nephropathy (IgAN)
Novartis announces European Medicines Agency (EMA) has granted orphan drug designation for iptacopan (LNP023) in IgA nephropathy (IgAN)